机译:None
National Institutes of Health;
National Institutes of Health;
National Institutes of Health;
Experimental Transplantation and Immunology Branch NCI NIH;
National Institutes of Health;
National Institutes of Health;
Leidos Biomedical Research Inc;
Hematology Branch National Heart Lung and Blood Institute;
Stem Cell Allogeneic Transplantation Section Hematology Branch National Heart Lung and Blood;
Laboratory of Transplantation Immunotherapy Hematology Branch National Heart Lung and Blood;
Sickle Cell Branch National Heart Lung and Blood Institute National Institutes of Health;
Experimental Transplantation and Immunology Branch Center for Cancer Research (CCR) National;
Center for Cancer Research/Pediatric Oncology Branch National Institutes of Health/National Cancer;
Experimental Transplantation and Immunology Branch NCI NIH;
Experimental Transplantation and Immunology Branch Center for Cancer Research (CCR) National;
Sickle Cell Branch National Heart Lung and Blood Institute National Institutes of Health;
Stem Cell Allogeneic Transplantation Section Hematology Branch National Heart Lung and Blood;
National Institutes of Health;
Experimental Transplantation and Immunology Branch Center for Cancer Research (CCR) National;
Center for Cancer Research/Pediatric Oncology Branch National Institutes of Health/National Cancer;
Sickle Cell Branch National Heart Lung and Blood Institute National Institutes of Health;
National Institutes of Health;
Experimental Transplantation and Immunology Branch NCI NIH;
Experimental Transplantation and Immunology Branch NCI NIH;
机译:None
机译:使用标准化监测和治疗方法的多种造血细胞移植(HCT)平台的巨细胞病毒(CMV)感染和疾病发生率及危险因素:从单一机构进行综合评价
机译:CytomeGalovirus感染发病率和不同造血细胞移植平台的风险因素使用标准化的监测和治疗方法:从单一机构的综合评估
机译:固体器官和造血干细胞移植受者感染CMV和疾病的全血和血浆中标准化巨细胞病毒(CMV)病毒载量阈值的比较
机译:CytomeGalovirus感染发病率和不同造血细胞移植平台的风险因素使用标准化的监测和治疗方法:从单一机构的综合评估